Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliograf¿a
[1]
Cribado de la osteoporosis en las personas mayores. Med Clin (Barc) 2002;116(Supl 1):77-82.
[2]
Incidencia, riesgo y evolución de las fracturas osteoporóticas de cuello de fémur en las mujeres en España, a partir de un modelo de Markov. Med Clin (Barc) 2000;114(Supl 2):63-7.
[3]
Medicina basada en la evidencia. Su empleo en el estudio de la osteoporosis y sus consecuencias. En: Reunión Científica de la Asociación Española de Evaluación de Tecnologías sanitarias; 1996, 21 de noviembre; Oviedo: Asociación Española de Evaluación de Tecnologías Sanitarias.
[4]
Prevalencia de osteoporosis determinada por densitometría en población femenina española. Med Clin (Barc) 2001;116:86-8.
[5]
Atención a la mujer perimenopáusica (1). Medifam 1992;2:127-34.
[6]
Sobre el uso clínico de los nuevos marcadores bioquímicos del metabolismo óseo. Med Clin (Barc) 1988;111:259-62.
[7]
The effectiveness of bone density measurement and associated treatments for prevention of fractures. An international collaborative review. Int J Technol Assess Health Care 1998;14:237-54.
[8]
N Engl J Med 1995;333:767-73.
[9]
Bone density measurement A systematic revies. Report from SBU. The Swedish Council on Technology Assesment in Health Care. J Intern Med 1997;241(Suppl 739):1-60.
[10]
Screening for postmenopausal osteoporosis: a review of the evidence for the U.S.Preventive Task Force. Ann Intern med 2002;137:529-41.
[11]
Evaluation of a hip fracture risk score for assesssing elderly women: the Melton Osteoporosis Fracture (MOF) Study. Osteoporos Int 2002;13:89-96.
[12]
An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 2000;11:192-202.
[13]
HRT and vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998;31:45-54.
[14]
Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
[15]
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73-9.
[16]
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
[17]
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
[18]
Effects of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteo-porosis. N Engl J Med 1995;333:1437-43.
[19]
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postme-nopausal osteoporosis a randomized controlled tial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
[20]
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
[21]
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2001;109:267-76.
[22]
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
[23]
Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Womens Health Inititive Randomized Controlled Trial. JAMA 2002;288:321-33.
[24]
Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.
[25]
Effect of Risedronato on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
[26]
Effect of calcum and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6.
[27]
The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
[28]
Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998;316:1858-63.
[29]
Washington: National Osteoporosis Foundation, 1998.
[30]
Executive summary: does evidence support the selective use of bone mineral density testing in well women? Intl J Technol Assess Health Care 1998;14:584-6.
[31]
Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Status report. Osteoporos Int 1998;8:1-S82.
[32]
JAMA 2001;285:785-95.
[33]
Clinical Preventive Health Care. Canada: Minister of Supply and Services, 1994.
[34]
Guide to clinical preventive service. 2nd ed. Baltimore: willians and Wilkins, 1996.
[35]
Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137:526-8.
[36]
Actividades preventivas en la mujer. Aten Primaria 2001;28(Supl 2):181-208.
[37]
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl):S1-34.
[38]
Guía de práctica clínica de la SEIOMM. Osteoporosis posmenopáusica, 2001.
[39]
Identification and fracture outcomes of un-diagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assesment. JAMA 2001;286:2815-22.
[40]
Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001;286:57-63.
[41]
Cribado de riesgo óseo mediante factoress clínicos en mujeres tras menopausia fisiológica. Med Clin (Barc) 1998;110:121-4.
[42]
An assesment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001;12:519-28.
[43]
Cronología de los estrógenos posmenopáusicos para conseguir un valor óptimo de la densidad mineral ósea. Rancho Bernardo Study. JAMA (ed. esp.) 1997;6:269-74.
[44]
Hormone replacement therapy and prevention of nonvertebral fractures. JAMA 2002;285:2891-7.
[45]
Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis or randomised trials. BMC Musculoskeletal Disorders 2001;2:7. Disponible en: www.biomedcentral.com/1471-2474/2/7
[46]
Breast cancer and hormone replacement therapy: collaborative reanalysis of data form 51 epidemiologicalstudies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-59.
[47]
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-12.
[48]
Noncardiovacular disease outcomes during 6,8 years of hormone replacement therapy. Heart and Estrogen/Progestin Replacement Study Follw-up (HERS II). JA-MA 2002;288:58-66.
[49]
Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000;132:689-96.
[50]
Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 2002;136:680-90.
[51]
Menopausal estrogen and estrogen-progestin replacement therapy and breas cancer risk. JAMA 2000;283:485-91.
[52]
Effect of oestrogen during menopause on risk and age at onset of Alzheimers disease. Lancet 1996;348:429-32.
[53]
Hormone replacement therapy and cognition. Systematic review and meta-analysis. JAMA 2001;285:1489-99.
[54]
Alzheimers Disease Cooperative Study. JAMA 2000;283:1007- 15.
[55]
Effect of estrogen plus progestin on global cognitive function in postmenopausal Women: the Womens Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663-72.
[56]
Estrogen plus progestin and the incidence ofdementia and mild cognitive impairment in postmenopausal women: the Womens Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2661-62.
[57]
Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 1998;37:87-94.
[58]
Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 1997;103:462-7.
[59]
Raloxifen and cardiovascular events in osteoporosis postmenopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
[60]
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
[61]
Effect or four monthly oral vitamin D 3 (cholecocalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469-74.
[62]
A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 2001;161:1161-72.
[63]
Phytoestrogen therapy for menopausal symptoms. BJM 2001;323:354-5.
[64]
Phytoestrogens for menopausal symptoms (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software, 2002.
[65]
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trail. JAMA 2001;285:1482-8.
[66]
Osteoporosis: a growing epidemic. Br J Clin Pract 1991;45:189-96.
[67]
Meta-analysis of the effectiveness of physical activity for the prevention of bone loss in postmenopausal women. Osteoporos Int 1997;7:331-7.
[68]
Aerobic exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis. J Am Geriatr Soc 1998;46:143-52.
[69]
The effect of the exercise training programs on bone mass: a meta-analysis of published controlled trials in pre-and postmenopausal women. Osteoporos Int 1999;9:1-12.
[70]
Aerobic exercise and bone density at the hip in posmenopausal women: a meta-analysis. Prev Med 1998;27: 798-807.
[71]
The effects of walking at the anaerobic threshold level on vertebral bone lossin posmenopausal women. Calcif Tissue Int 1993;52:411-4.
[72]
Optimal calcium intake. JAMA 1994;272:1942-8.
[73]
Cigarette Somoking, alcohol consumption, and risk of hip fracture in women. Arch Intern Med 2001;161:983-8.
[74]
Effect of carbamacepine and valproate on bone mineral density. J Pedatr 1995;127:256-62.
[75]
Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest 1999;116:1733-49.
[76]
Bone mineral density and bone turnover in asthmatics treated with long-term inhales or oral glucocorticoids. J Bone Miner Res 1998;13:1283-9.
[77]
Side effects of inhales corticosteroid. J Allergy Clin Inmunol 1998;102:705-13.
[78]
Randomised controlled trial of a general practice programme of home based to prevents falls in elderly women. Br Med J 1997;315:1065-9.
[79]
Effectiveness and economic evaluation of a nurse delivered home exercise programme to prevent falls. Randomised controlled trial. BMJ 2001;24:697-701.
[80]
Interventions to reduce the incidence of falling in the elderly. Cochrane Database Syst Rev 1999;(1).
[81]
Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
[82]
Recomendaciones para el uso de la densitometría ósea en el diagnóstico y tratamiento de la osteoporosis. Rev Calidad Asist 2002;17:644-51.
[83]
Guidelines for the treatment of postmenopausal osteoporosis for general practitioners. Austalian Family Physicians 2002;31:921-8.
